A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma

被引:26
作者
Kucukay, Fahrettin [1 ]
Badem, Serife [1 ]
Karan, Adnan [1 ]
Ozdemir, Mustafa [1 ]
Okten, Riza S. [1 ]
Ozbulbul, Nilgun I. [1 ]
Kucukay, Murat B. [4 ]
Unlu, Ipek [2 ]
Bostanci, Erdal B. [2 ]
Akdogan, Meral [3 ]
机构
[1] Turkiye Yuksek Ihtisas Hosp, Dept Intervent Radiol, TR-06100 Ankara, Turkey
[2] Turkiye Yuksek Ihtisas Hosp, Dept Gastrointestinal Surg, TR-06100 Ankara, Turkey
[3] Turkiye Yuksek Ihtisas Hosp, Dept Gastroenterol, TR-06100 Ankara, Turkey
[4] Lokman Hekim Hosp, Dept Internal Med, Ankara, Turkey
关键词
ELUTING BEADS; EMBOLIZATION; HEPATECTOMY; SURVIVAL; ABLATION; SAFETY; LIVER;
D O I
10.1016/j.jvir.2015.07.017
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To compare doxorubicin-loaded HepaSphere transarterial chemoembolization versus conventional transarterial chemoembolization in terms of survival, time to recurrence, acute reversible hepatotoxicity, postembolization syndrome, and chemoembolization-related mortality and morbidity. Materials and Methods: One hundred twenty-six patients (103 men, 23 women; mean age, 64.3 y) with unresectable hepatocellular carcinoma (HCC) who underwent conventional chemoembolization between January 2007 and March 2011 or drug-eluting embolic (DEE)-chemoembolization (after the protocol change) between March 2011 and October 2014 were included in a retrospective analysis. Primary outcome-measures were survival and time to recurrence. Secondary outcome measures were frequency of recurrence, technical success, acute reversible hepatotoxicity, postembolization syndrome, and chemoembolization-related mortality and morbidity. Results: The technical success rate was 97.1%. There Were no significant differences between the conventional and DEE chemoembolization groups with regard to mean survival duration (39:0 vs 37.4 mo), recurrence (32.9% vs 39.6%), postembolization syndrome (90% vs 89%), and chemoembolization-related mortality (5.5% vs 1.9%) and morbidity (9.6% vs 9.4%; P > .05). The time; to recurrence was shorter in DEE chemoembolization treated patients than in conventional chemoembolization-treated patients (5.0 vs 11.5 mo; P = .006), and acute reversible hepatotoxicity occurred more frequently after conventional chemoembolization (P = .019). Conclusions: Conventional chemoembolization and DEE chemoembolization were safe and effective interventions for unresectable HCC. DEE chemoembolization was not better than conventional chemoembolization in terms of survival and was associated with a shorter time to recurrence. Acute reversible hepatotoxicity occurred more frequently after conventional chemoembolization.
引用
收藏
页码:1622 / 1629
页数:8
相关论文
共 50 条
  • [41] Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula
    Cai, Liang
    Li, Honglu
    Guo, Jiang
    Zhao, Wenpeng
    Duan, Youjia
    Hou, Xiaopu
    Cheng, Long
    Du, Hongliu
    Shao, Xihong
    Diao, Zhenying
    Hao, Yiwei
    Zheng, Xinmei
    Li, Changqing
    Li, Wei
    [J]. CANCER BIOLOGY & THERAPY, 2022, 23 (01) : 89 - 95
  • [42] Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres(R) Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis
    Liang, Bin
    Makamure, Joyman
    Shu, Shenglei
    Zhang, Lijie
    Sun, Tao
    Zheng, Chuansheng
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Balloon-Occluded Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma: A Single-Center US Preliminary Experience
    Goldman, Daryl T.
    Singh, Manu
    Patel, Rahul S.
    Nowakowski, F. Scott
    Bishay, Vivian
    Ranade, Mona
    Lookstein, Robert A.
    Fischman, Aaron M.
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 30 (03) : 342 - 346
  • [44] Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
    Zhang, Weihua
    Chen, Lei
    Cao, Yanyan
    Sun, Bo
    Ren, Yanqiao
    Sun, Tao
    Zheng, Chuansheng
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 5391 - 5402
  • [45] Conventional transarterial chemoembolization followed by irreversible electroporation for hepatocellular carcinoma
    Zhao, Meng
    Li, Fubao
    Tian, Chuan
    Cai, Duo
    Wang, Congxiao
    [J]. BMC CANCER, 2025, 25 (01)
  • [46] Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study
    Shi, Qin
    Chen, Dandan
    Zhou, Chen
    Liu, Jiacheng
    Huang, Songjiang
    Yang, Chongtu
    Xiong, Bin
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 5461 - 5468
  • [47] Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study
    Yan, Liangliang
    Chen, Lei
    Qian, Kun
    Kan, Xuefeng
    Zhang, Hongsen
    Liang, Bin
    Zheng, Chuansheng
    [J]. CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 3901 - 3912
  • [48] Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm
    Miyayama, Shiro
    Kikuchi, Yuzo
    Yoshida, Masanori
    Yamashiro, Masashi
    Sugimori, Natsuki
    Ikeda, Rie
    Okimura, Kotaro
    Sakuragawa, Naoko
    Ueda, Teruyuki
    Sanada, Taku
    Watanabe, Hiroyuki
    Notsumata, Kazuo
    [J]. HEPATOLOGY RESEARCH, 2019, 49 (07) : 787 - 798
  • [49] Single-Center Phase II Trial of Transarterial Chemoembolization With Drug-Eluting Beads for Patients With Unresectable Hepatocellular Carcinoma Initial Experience in the United States
    Reyes, Diane K.
    Vossen, Josephina A.
    Kamel, Ihab R.
    Azad, Nilofer S.
    Wahlin, Tamara A.
    Torbenson, Michael S.
    Choti, Michael A.
    Geschwind, Jean-Francois H.
    [J]. CANCER JOURNAL, 2009, 15 (06) : 526 - 532
  • [50] Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma
    Moreno-Luna, Laura E.
    Yang, Ju Dong
    Sanchez, William
    Paz-Fumagalli, Ricardo
    Harnois, Denise M.
    Mettler, Teresa A.
    Gansen, Denise N.
    de Groen, Piet C.
    Lazaridis, Konstantinos N.
    Menon, K. V. Narayanan
    LaRusso, Nicholas F.
    Alberts, Steven R.
    Gores, Gregory J.
    Fleming, Chad J.
    Slettedahl, Seth W.
    Harmsen, William S.
    Therneau, Terry M.
    Wiseman, Gregory A.
    Andrews, James C.
    Roberts, Lewis R.
    [J]. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 36 (03) : 714 - 723